Law Offices of Howard G. Smith announces an investigation on behalf of Nabriva Therapeutics plc (Nabriva or the Company) (NASDAQ: NBRV) investors concerning the Company and its officers possible violations of federal securities laws.
On April 30, 2019, the Company revealed that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for ONTEPO„¢ (fosfomycin) for injection for the treatment of complicated urinary tract infections. According to the CRL, the Company had to address certain issues related to facility inspections and manufacturing deficiencies at one of Nabrivas contract manufacturers before the FDA would approve the NDA.
On this news, the Companys share price fell $0.82 per share, more than 27%, to close at $2.17 per share on May 1 2019, thereby injuring investors.
If you purchased Nabriva securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.